Lv41
434 积分 2023-05-19 加入
IFN Signaling and ICB Resistance: Time is on Tumor’s Side
3小时前
待确认
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
5小时前
已完结
Interleukin-7 receptor expression: intelligent design
6小时前
已完结
Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
3天前
已完结
T Cell Exhaustion
10天前
已完结
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
11天前
已完结
HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode
11天前
已完结
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
12天前
已完结
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
14天前
已完结
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)
14天前
已完结
皖公网安备34019202002308
